Nektar Therapeutics [NKTR] stock is trading at $59.6, up 1.21%. An important factor to consider is whether the stock is rising or falling in short-term value. The NKTR shares have gain 19.46% over the last week, with a monthly amount glided 120.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on June 24, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $120 from $6.50. Previously, BTIG Research reaffirmed its Buy rating on June 24, 2025, and elevated its price target to $100. On April 11, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $2 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $6 on March 14, 2025. B. Riley Securities initiated its recommendation with a Buy and recommended $4 as its price target on January 08, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on December 10, 2024, and assigned it a price target of $6.50. In a note dated November 04, 2024, Piper Sandler initiated an Overweight rating and provided a target price of $7 on this stock.
Nektar Therapeutics [NKTR] stock has fluctuated between $0.43 and $59.58 over the past year. Currently, Wall Street analysts expect the stock to reach $99 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $59.6 at the most recent close of the market. An investor can expect a potential return of 66.11% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Nektar Therapeutics [NASDAQ:NKTR] reported sales of 74.93M for the trailing twelve months, which represents a drop of -52.42%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -1.34%, Pretax Profit Margin comes in at -1.55%, and Net Profit Margin reading is -1.63%. To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -4.93 and Total Capital is -0.74. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -3.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 58.13 points at the first support level, and at 56.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 61.07, and for the 2nd resistance point, it is at 62.53.
Ratios To Look Out For
For context, Nektar Therapeutics’s Current Ratio is 2.61. On the other hand, the Quick Ratio is 2.61, and the Cash Ratio is 0.6. Considering the valuation of this stock, the price to sales ratio is 15.13.
Transactions by insiders
Recent insider trading involved ROBIN HOWARD W, President & CEO, that happened on Sep 09 ’25 when 6666.0 shares were sold. Officer, ROBIN HOWARD W completed a deal on Sep 09 ’25 to buy 6666.0 shares. Meanwhile, Chief R&D Officer Zalevsky Jonathan sold 1721.0 shares on Sep 04 ’25.
